ARMO BioSciences's Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival

It is particularly promising to see these high, durable responses in advanced NSCLC patients with low as well as high PD-L1 expression and in intermediate to poor risk advanced RCC patients who have received 2 or more prior therapies."09/11/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news